(Q40940040)

25 September 2017

1 reference

title

Losartan potassium: a review of its pharmacology, clinical efficacy and tolerability in the management of hypertension (English)

1 reference

25 September 2017

1 reference

1 reference

K L Goa

1

1 reference

PubMed ID

8861549

25 September 2017

A J Wagstaff

series ordinal

2

1 reference

25 September 2017

1 May 1996

1 reference

25 September 2017

1 reference

25 September 2017

51

1 reference

25 September 2017

5

1 reference

25 September 2017

820-845

1 reference

https://scigraph.springernature.com/pub.10.2165/00003495-199651050-00008

25 September 2017

0 references

cites work

The effects of angiotensin II receptor blockade with losartan on systemic blood pressure and renal and extrarenal prostaglandin synthesis in women with essential hypertension

1 reference

12 December 2020

Modulation of the renin-angiotensin-aldosterone system and cough.

1 reference

12 December 2020

Type-1 and type-2 angiotensin II receptors in fetal rat brain

1 reference

12 December 2020

Effects of losartan on a background of hydrochlorothiazide in patients with hypertension

1 reference

12 December 2020

The preclinical basis of the therapeutic evaluation of losartan.

1 reference

12 December 2020

Acute renal excretory actions of losartan in spontaneously hypertensive rats: role of AT2 receptors, prostaglandins, kinins and nitric oxide

1 reference

12 December 2020

Biotransformation of losartan to its active carboxylic acid metabolite in human liver microsomes. Role of cytochrome P4502C and 3A subfamily members

1 reference

12 December 2020

Effect of multiple doses of losartan on the pharmacokinetics of single doses of digoxin in healthy volunteers

1 reference

12 December 2020

The metabolism of DuP 753, a nonpeptide angiotensin II receptor antagonist, by rat, monkey, and human liver slices

1 reference

12 December 2020

Antihypertensive and anti-albuminuric effects of losartan potassium and felodipine in Chinese elderly hypertensive patients with or without non-insulin-dependent diabetes mellitus.

1 reference

12 December 2020

Comparison of the transplacental transfer of enalapril, captopril and losartan in sheep

1 reference

12 December 2020

Hypotensive action of DuP 753, an angiotensin II antagonist, in spontaneously hypertensive rats. Nonpeptide angiotensin II receptor antagonists: X

1 reference

12 December 2020

Angiotensin II receptor subtypes: selective antagonists and functional correlates

1 reference

12 December 2020

Localization of components of the renin-angiotensin system and site of action of inhibitors.

1 reference

12 December 2020

Pharmacokinetics and biochemical efficacy after single and multiple oral administration of losartan, an orally active nonpeptide angiotensin II receptor antagonist, in humans

1 reference

12 December 2020

Effects of cimetidine on pharmacokinetics and pharmacodynamics of losartan, an AT1-selective non-peptide angiotensin II receptor antagonist

1 reference

12 December 2020

Losartan in patients with renal insufficiency.

1 reference

12 December 2020

Comparison of angiotensin-converting enzyme inhibition with angiotensin II receptor antagonism in the human forearm

1 reference

12 December 2020

Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension.

1 reference

12 December 2020

Management guidelines in essential hypertension: report of the second working party of the British Hypertension Society

1 reference

12 December 2020

Absence of a pharmacokinetic interaction between losartan and hydrochlorothiazide.

1 reference

12 December 2020

EXP3174, a metabolite of losartan (MK954, DuP753) is more potent than losartan in blocking the angiotensin ll-induced responses in vascular smooth muscle cells

1 reference

12 December 2020

Effects of the angiotensin II antagonist losartan in hypertensive patients with renal disease

1 reference

12 December 2020

Role of angiotensin in pressure overload-induced hypertrophy in rats: effects of angiotensin-converting enzyme inhibitors, an AT1 receptor antagonist, and surgical reversal.

1 reference

12 December 2020

Oxidation of the angiotensin II receptor antagonist losartan (DuP 753) in human liver microsomes. Role of cytochrome P4503A(4) in formation of the active metabolite EXP3174

1 reference

12 December 2020

Identification of two subtypes in the rat type I angiotensin II receptor

1 reference

12 December 2020

Human plasma protein binding of the angiotensin II receptor antagonist losartan potassium (DuP 753/MK 954) and its pharmacologically active metabolite EXP3174

1 reference

12 December 2020

Efficacy and tolerability of losartan versus enalapril alone or in combination with hydrochlorothiazide in patients with essential hypertension

1 reference

12 December 2020

[3H]DUP 753, a highly potent and specific radioligand for the angiotensin II-1 receptor subtype

1 reference

12 December 2020

Effects of losartan, a nonpeptide angiotensin II receptor antagonist, on cardiac hypertrophy and the tissue angiotensin II content in spontaneously hypertensive rats

1 reference

12 December 2020

Angiotensin II receptor subtypes and their selective nonpeptide ligands

1 reference

12 December 2020

DuP 753 is a specific antagonist for the angiotensin receptor.

1 reference

12 December 2020

Antihypertensive efficacy and tolerability of once daily losartan potassium compared with captopril in patients with mild to moderate essential hypertension.

1 reference

12 December 2020

Angiotensin II antagonism improves the lipoprotein profile in patients with nephrotic syndrome.

1 reference

12 December 2020

Losartan does not affect the pharmacokinetics and pharmacodynamics of warfarin

1 reference

12 December 2020

Effect of acute and chronic losartan therapy on active and inactive renin and active renin glycoforms

1 reference

12 December 2020

Further studies on the selectivity of DuP 753, a nonpeptide angiotensin II receptor antagonist

1 reference

12 December 2020

Angiotensin II receptor antagonist delays renal damage and stroke in salt-loaded Dahl salt-sensitive rats

1 reference

12 December 2020

Angioedema induced by the angiotensin II blocker losartan

1 reference

12 December 2020

Losartan potassium as initial therapy in patients with severe hypertension

1 reference

12 December 2020

Renal hemodynamics in essential hypertensives treated with losartan

1 reference

12 December 2020

Randomised, double-blind, parallel study of the anti-hypertensive efficacy and safety of losartan potassium compared with felodipine ER in elderly patients with mild to moderate hypertension

1 reference

12 December 2020

Angiotensin II receptors and angiotensin II receptor antagonists.

1 reference

12 December 2020

Controversies in the diagnosis and treatment of hypertension: a personal review of JNC V.

1 reference

12 December 2020

The pharmacokinetics of losartan in renal insufficiency

1 reference

12 December 2020

Hemodynamic and humoral effects of the angiotensin II antagonist losartan in essential hypertension

1 reference

12 December 2020

Competitive antagonism of pressor responses to angiotensin II and angiotensin III by the angiotensin II-1 receptor ligand losartan

1 reference

12 December 2020

Left ventricular fibrosis in renovascular hypertensive rats. Effect of losartan and spironolactone

1 reference

12 December 2020

Additive effects of combined angiotensin-converting enzyme inhibition and angiotensin II antagonism on blood pressure and renin release in sodium-depleted normotensives

1 reference

12 December 2020

Effects of losartan on angiotensin and bradykinin peptides and angiotensin-converting enzyme

1 reference

12 December 2020

Nonpeptide angiotensin II receptor antagonists. VII. Cellular and biochemical pharmacology of DuP 753, an orally active antihypertensive agent.

1 reference

12 December 2020

Losartan with hydrochlorothiazide in the treatment of hypertension.

1 reference

12 December 2020

Blood pressure effects of the angiotensin II receptor blocker, losartan

1 reference

12 December 2020

Cloning, characterization, and expression of two angiotensin receptor (AT-1) isoforms from the mouse genome.

1 reference

12 December 2020

Drug concentration response relationships in normal volunteers after oral administration of losartan, an angiotensin II receptor antagonist

1 reference

12 December 2020

Phenobarbital minimally alters plasma concentrations of losartan and its active metabolite E-3174

1 reference

12 December 2020

Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension

1 reference

12 December 2020

Preliminary biochemical characterization of two angiotensin II receptor subtypes

1 reference

12 December 2020

Control of blood pressure and end-organ damage in maturing salt-loaded stroke-prone spontaneously hypertensive rats by oral angiotensin II receptor blockade

1 reference

12 December 2020

Dose-response relationships following oral administration of DuP 753 to normal humans

1 reference

12 December 2020

Angiotensin II stimulation of left ventricular hypertrophy in adult rat heart. Mediation by the AT1 receptor

1 reference

12 December 2020

Identification of angiotensin II receptor subtypes

1 reference

12 December 2020

Molecular cloning and sequencing of the gene encoding human angiotensin II type 1 receptor

1 reference

12 December 2020

Nonpeptide angiotensin II receptor antagonists. XI. Pharmacology of EXP3174: an active metabolite of DuP 753, an orally active antihypertensive agent

1 reference

12 December 2020

Controversies regarding the recommendations of the Fifth Report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure

1 reference

12 December 2020

The effect of angiotensin II receptor blockade on insulin sensitivity and sympathetic nervous system activity in primary hypertension.

1 reference

12 December 2020

Functional evidence that the angiotensin antagonist losartan crosses the blood-brain barrier in the rat.

1 reference

12 December 2020

Losartan potassium, a nonpeptide antagonist of angiotensin II, chronically administered p.o. does not readily cross the blood-brain barrier

1 reference

12 December 2020

Differential effects of oral losartan and enalapril on local venous and systemic pressor responses to angiotensin I and II in healthy men

1 reference

12 December 2020

The fifth report of the Joint National Committee on Detection, Evaluation, and Treatment of High Blood Pressure (JNC V)

1 reference

12 December 2020

Pilot study of the uricosuric effect of DuP-753, a new angiotensin II receptor antagonist, in healthy subjects

1 reference

12 December 2020

In Vitro Pharmacology of DuP 753

1 reference

12 December 2020

Salt-dependent renal effects of an angiotensin II antagonist in healthy subjects

1 reference

12 December 2020

Nonpeptide angiotensin II receptor antagonists. IX. Antihypertensive activity in rats of DuP 753, an orally active antihypertensive agent

1 reference

12 December 2020

Efficacy and tolerability of losartan potassium and atenolol in patients with mild to moderate essential hypertension

1 reference

12 December 2020

Angiotensin II receptor antagonists in heart failure: rationale and design of the evaluation of losartan in the elderly (ELITE) trial

1 reference

12 December 2020

Effect of losartan, an angiotensin II receptor antagonist, on response of cortisol and aldosterone to adrenocorticotrophic hormone.

1 reference

12 December 2020

Dose-ranging study of the angiotensin type I receptor antagonist losartan (DuP753/MK954), in salt-deplete normal man

1 reference

12 December 2020

Effects of losartan on blood pressure, plasma renin activity, and angiotensin II in volunteers

1 reference

12 December 2020

Reversible ageusia associated with losartan

1 reference

12 December 2020

Midwall left ventricular performance in salt-loaded Dahl rats: effect of AT1 angiotensin II inhibition.

1 reference

12 December 2020

Losartan and severe migraine

1 reference

12 December 2020

Safety and tolerability of losartan potassium, an angiotensin II receptor antagonist, compared with hydrochlorothiazide, atenolol, felodipine ER, and angiotensin-converting enzyme inhibitors for the treatment of systemic hypertension

1 reference

12 December 2020

Cough and inhibition of the renin-angiotensin system.

1 reference

12 December 2020

Cough with angiotensin converting enzyme inhibitors: how much of a problem?

1 reference

12 December 2020

Effect of losartan on haematology and haemorheology in elderly patients with essential hypertension: a pilot study

1 reference

12 December 2020

Losartan and low-dose hydrochlorothiazide in patients with essential hypertension. A double-blind, placebo-controlled trial of concomitant administration compared with individual components

1 reference

12 December 2020

Regression of cardiac hypertrophy and myosin isoenzyme patterns by losartan and captopril in renovascular hypertensive rats

1 reference

12 December 2020

Stroke prevention by losartan in stroke-prone spontaneously hypertensive rats

1 reference

12 December 2020

Biochemical effects of losartan, a nonpeptide angiotensin II receptor antagonist, on the renin-angiotensin-aldosterone system in hypertensive patients

1 reference

12 December 2020

Losartan's protective effects in stroke-prone spontaneously hypertensive rats persist durably after treatment withdrawal.

1 reference

12 December 2020

The clinical potential of renin inhibitors and angiotensin antagonists

1 reference

12 December 2020

Pharmacokinetics of losartan, an angiotensin II receptor antagonist, and its active metabolite EXP3174 in humans

1 reference

12 December 2020

A randomized, placebo-controlled, double-blind, parallel study of various doses of losartan potassium compared with enalapril maleate in patients with essential hypertension

1 reference

12 December 2020

Effects of enalapril versus losartan on regression of volume overload-induced cardiac hypertrophy in rats

1 reference

12 December 2020

Nonpeptide angiotensin II receptor antagonists. VIII. Characterization of functional antagonism displayed by DuP 753, an orally active antihypertensive agent.

1 reference

12 December 2020

Angiotensin receptor antagonists: focus on losartan

1 reference

12 December 2020

Rationale for the Chemical Development of Angiotensin II Receptor Antagonists

1 reference

12 December 2020

Simultaneous determination of a novel angiotensin II receptor blocking agent, losartan, and its metabolite in human plasma and urine by high-performance liquid chromatography

1 reference

12 December 2020

Effects of modulators of the renin-angiotensin-aldosterone system on cough. Losartan Cough Study Group.

1 reference

12 December 2020

10.2165/00003495-199651050-00008

Identifiers

DOI

1 reference

PubMed ID

8861549

Dimensions Publication ID

25 September 2017

0 references

1 reference

PubMed ID

8861549